Blockade of tumor cell transforming growth factor-βs enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy

Tohru Ohmori, Jin Long Yang, James O. Price, Carlos L. Arteaga

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

We have examined the effect of neutralizing TGF-β antibodies on cisplatin-mediated cytotoxicity against MDA-231 human breast tumor cell spheroids. These tridimensional in vitro systems have been shown to recapitulate the drug sensitivity pattern of tumor cells in vivo. MDA-231 tumor cell spheroids exhibit higher protein levels of the cyclin-dependent kinase (Cdk) inhibitors p21 and p27 and >10-fold lower Cdk2 activity compared to adherent cell monolayers, as well as pRb hypophosphorylation, a predominant G1 population, and a cisplatin 1-h IC50 of approximately 100 μM. Treatment of MDA-231 cells in monolayer with cisplatin for 1 h, subsequently grown as spheroids, increased steady-state TGF-β1 mRNA levels, secretion of active TGF-β, cellular Cdk2 activity, pRb phosphorylation, and p21 protein levels, while downregulating p27. Accumulation of cells in G2M and progression into S were noted 48 h after treatment with 100 μM cisplatin. We tested whether drug-induced upregulation of TGF-β1 and p21, perhaps by preventing cell cycle progression, were protective mechanisms against drug-mediated toxicity by using neutralizing anti-TGF-β antibodies. Anti-TGF-β antibodies diminished the induction of p21, enhanced the activation of Cdk2, and facilitated progression into S and G2M following cisplatin treatment. This resulted in a >twofold enhancement of drug-induced DNA fragmentation and a shift in the cisplatin 1-h IC50 from 100 to <10 μM. These data suggest that tumor cell TGF-β1 may protect from DNA damage and that postchemotherapy administration of TGF-β inhibitors may facilitate progression beyond G1/S, potentially increasing the efficacy of cytotoxic chemotherapy.

Original languageEnglish (US)
Pages (from-to)350-359
Number of pages10
JournalExperimental Cell Research
Volume245
Issue number2
DOIs
StatePublished - Dec 15 1998

Fingerprint

Transforming Growth Factors
Cell Cycle
Cisplatin
Breast Neoplasms
Drug Therapy
Neoplasms
Neutralizing Antibodies
Inhibitory Concentration 50
Anti-Idiotypic Antibodies
Pharmaceutical Preparations
Cyclin-Dependent Kinase Inhibitor p21
Cyclin-Dependent Kinase Inhibitor p27
DNA Fragmentation
Drug-Related Side Effects and Adverse Reactions
DNA Damage
Proteins
Up-Regulation
Therapeutics
Down-Regulation
Phosphorylation

Keywords

  • Apoptosis
  • Breast carcinoma
  • Cell cycle
  • Cisplatin
  • Spheroids
  • Transforming growth factor-β

ASJC Scopus subject areas

  • Cell Biology

Cite this

Blockade of tumor cell transforming growth factor-βs enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. / Ohmori, Tohru; Yang, Jin Long; Price, James O.; Arteaga, Carlos L.

In: Experimental Cell Research, Vol. 245, No. 2, 15.12.1998, p. 350-359.

Research output: Contribution to journalArticle

@article{d9cf8b69572e447eb6cbf1c99b20a9f8,
title = "Blockade of tumor cell transforming growth factor-βs enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy",
abstract = "We have examined the effect of neutralizing TGF-β antibodies on cisplatin-mediated cytotoxicity against MDA-231 human breast tumor cell spheroids. These tridimensional in vitro systems have been shown to recapitulate the drug sensitivity pattern of tumor cells in vivo. MDA-231 tumor cell spheroids exhibit higher protein levels of the cyclin-dependent kinase (Cdk) inhibitors p21 and p27 and >10-fold lower Cdk2 activity compared to adherent cell monolayers, as well as pRb hypophosphorylation, a predominant G1 population, and a cisplatin 1-h IC50 of approximately 100 μM. Treatment of MDA-231 cells in monolayer with cisplatin for 1 h, subsequently grown as spheroids, increased steady-state TGF-β1 mRNA levels, secretion of active TGF-β, cellular Cdk2 activity, pRb phosphorylation, and p21 protein levels, while downregulating p27. Accumulation of cells in G2M and progression into S were noted 48 h after treatment with 100 μM cisplatin. We tested whether drug-induced upregulation of TGF-β1 and p21, perhaps by preventing cell cycle progression, were protective mechanisms against drug-mediated toxicity by using neutralizing anti-TGF-β antibodies. Anti-TGF-β antibodies diminished the induction of p21, enhanced the activation of Cdk2, and facilitated progression into S and G2M following cisplatin treatment. This resulted in a >twofold enhancement of drug-induced DNA fragmentation and a shift in the cisplatin 1-h IC50 from 100 to <10 μM. These data suggest that tumor cell TGF-β1 may protect from DNA damage and that postchemotherapy administration of TGF-β inhibitors may facilitate progression beyond G1/S, potentially increasing the efficacy of cytotoxic chemotherapy.",
keywords = "Apoptosis, Breast carcinoma, Cell cycle, Cisplatin, Spheroids, Transforming growth factor-β",
author = "Tohru Ohmori and Yang, {Jin Long} and Price, {James O.} and Arteaga, {Carlos L.}",
year = "1998",
month = "12",
day = "15",
doi = "10.1006/excr.1998.4261",
language = "English (US)",
volume = "245",
pages = "350--359",
journal = "Experimental Cell Research",
issn = "0014-4827",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Blockade of tumor cell transforming growth factor-βs enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy

AU - Ohmori, Tohru

AU - Yang, Jin Long

AU - Price, James O.

AU - Arteaga, Carlos L.

PY - 1998/12/15

Y1 - 1998/12/15

N2 - We have examined the effect of neutralizing TGF-β antibodies on cisplatin-mediated cytotoxicity against MDA-231 human breast tumor cell spheroids. These tridimensional in vitro systems have been shown to recapitulate the drug sensitivity pattern of tumor cells in vivo. MDA-231 tumor cell spheroids exhibit higher protein levels of the cyclin-dependent kinase (Cdk) inhibitors p21 and p27 and >10-fold lower Cdk2 activity compared to adherent cell monolayers, as well as pRb hypophosphorylation, a predominant G1 population, and a cisplatin 1-h IC50 of approximately 100 μM. Treatment of MDA-231 cells in monolayer with cisplatin for 1 h, subsequently grown as spheroids, increased steady-state TGF-β1 mRNA levels, secretion of active TGF-β, cellular Cdk2 activity, pRb phosphorylation, and p21 protein levels, while downregulating p27. Accumulation of cells in G2M and progression into S were noted 48 h after treatment with 100 μM cisplatin. We tested whether drug-induced upregulation of TGF-β1 and p21, perhaps by preventing cell cycle progression, were protective mechanisms against drug-mediated toxicity by using neutralizing anti-TGF-β antibodies. Anti-TGF-β antibodies diminished the induction of p21, enhanced the activation of Cdk2, and facilitated progression into S and G2M following cisplatin treatment. This resulted in a >twofold enhancement of drug-induced DNA fragmentation and a shift in the cisplatin 1-h IC50 from 100 to <10 μM. These data suggest that tumor cell TGF-β1 may protect from DNA damage and that postchemotherapy administration of TGF-β inhibitors may facilitate progression beyond G1/S, potentially increasing the efficacy of cytotoxic chemotherapy.

AB - We have examined the effect of neutralizing TGF-β antibodies on cisplatin-mediated cytotoxicity against MDA-231 human breast tumor cell spheroids. These tridimensional in vitro systems have been shown to recapitulate the drug sensitivity pattern of tumor cells in vivo. MDA-231 tumor cell spheroids exhibit higher protein levels of the cyclin-dependent kinase (Cdk) inhibitors p21 and p27 and >10-fold lower Cdk2 activity compared to adherent cell monolayers, as well as pRb hypophosphorylation, a predominant G1 population, and a cisplatin 1-h IC50 of approximately 100 μM. Treatment of MDA-231 cells in monolayer with cisplatin for 1 h, subsequently grown as spheroids, increased steady-state TGF-β1 mRNA levels, secretion of active TGF-β, cellular Cdk2 activity, pRb phosphorylation, and p21 protein levels, while downregulating p27. Accumulation of cells in G2M and progression into S were noted 48 h after treatment with 100 μM cisplatin. We tested whether drug-induced upregulation of TGF-β1 and p21, perhaps by preventing cell cycle progression, were protective mechanisms against drug-mediated toxicity by using neutralizing anti-TGF-β antibodies. Anti-TGF-β antibodies diminished the induction of p21, enhanced the activation of Cdk2, and facilitated progression into S and G2M following cisplatin treatment. This resulted in a >twofold enhancement of drug-induced DNA fragmentation and a shift in the cisplatin 1-h IC50 from 100 to <10 μM. These data suggest that tumor cell TGF-β1 may protect from DNA damage and that postchemotherapy administration of TGF-β inhibitors may facilitate progression beyond G1/S, potentially increasing the efficacy of cytotoxic chemotherapy.

KW - Apoptosis

KW - Breast carcinoma

KW - Cell cycle

KW - Cisplatin

KW - Spheroids

KW - Transforming growth factor-β

UR - http://www.scopus.com/inward/record.url?scp=0032534450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032534450&partnerID=8YFLogxK

U2 - 10.1006/excr.1998.4261

DO - 10.1006/excr.1998.4261

M3 - Article

C2 - 9851876

AN - SCOPUS:0032534450

VL - 245

SP - 350

EP - 359

JO - Experimental Cell Research

JF - Experimental Cell Research

SN - 0014-4827

IS - 2

ER -